These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31867597)

  • 1. Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy.
    Thomas A; Hammarlund E; Gao L; Holman S; Michel KG; Glesby M; Villacres MC; Golub ET; Roan NR; French AL; Augenbraun MH; Slifka MK
    J Infect Dis; 2020 Jun; 222(2):243-251. PubMed ID: 31867597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies Induced by Smallpox Vaccination after at Least 45 Years Cross-React with and In Vitro Neutralize Mpox Virus: A Role for Polyclonal B Cell Activation?
    Mariotti S; Venturi G; Chiantore MV; Teloni R; De Santis R; Amendola A; Fortuna C; Marsili G; Grilli G; Lia MS; Kiros ST; Lagi F; Bartoloni A; Iacobino A; Cresta R; Lastilla M; Biselli R; Di Bonito P; Lista F; Nisini R
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients.
    Avelino-Silva VI; Miyaji KT; Mathias A; Costa DA; de Carvalho Dias JZ; Lima SB; Simoes M; Freire MS; Caiaffa-Filho HH; Hong MA; Lopes MH; Sartori AM; Kallas EG
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):189-95. PubMed ID: 26361176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
    Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
    J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Pathogen-Specific Immune Reconstitution in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Children.
    Muenchhoff M; Adland E; Roider J; Kløverpris H; Leslie A; Boehm S; Keppler OT; Ndung'u T; Goulder PJR
    J Infect Dis; 2019 Apr; 219(9):1407-1417. PubMed ID: 30624717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.
    Okulicz JF; Le TD; Agan BK; Camargo JF; Landrum ML; Wright E; Dolan MJ; Ganesan A; Ferguson TM; Smith DM; Richman DD; Little SJ; Clark RA; He W; Ahuja SK
    JAMA Intern Med; 2015 Jan; 175(1):88-99. PubMed ID: 25419650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus.
    Demkowicz WE; Littaua RA; Wang J; Ennis FA
    J Virol; 1996 Apr; 70(4):2627-31. PubMed ID: 8642697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pattern and magnitude of T cell subsets reconstitution during ten years of ART with viral suppression in HIV-infected patients.
    Lu L; Li X; Liu X; Qiu Z; Han Y; Song X; Li Y; Li X; Cao W; Lv W; Dou Z; Li T
    Aging (Albany NY); 2022 Dec; 14(23):9647-9667. PubMed ID: 36490352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
    Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
    PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
    Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
    J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.
    Kaufmann GR; Zaunders JJ; Cunningham P; Kelleher AD; Grey P; Smith D; Carr A; Cooper DA
    AIDS; 2000 Dec; 14(17):2643-51. PubMed ID: 11125882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype.
    Munier CML; van Bockel D; Bailey M; Ip S; Xu Y; Alcantara S; Liu SM; Denyer G; Kaplan W; ; Suzuki K; Croft N; Purcell A; Tscharke D; Cooper DA; Kent SJ; Zaunders JJ; Kelleher AD
    Vaccine; 2016 Oct; 34(44):5251-5261. PubMed ID: 27639281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy.
    Resino S; Galán I; Pérez A; León JA; Seoane E; Gurbindo D; Muñoz-Fernandez MA
    Clin Exp Immunol; 2004 Sep; 137(3):570-7. PubMed ID: 15320908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
    J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.
    Gamberg J; Barrett L; Bowmer I; Howley C; Grant M
    J Clin Immunol; 2004 Mar; 24(2):115-24. PubMed ID: 15024178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.
    de Armas LR; Pallikkuth S; Rinaldi S; Pahwa R; Pahwa S
    AIDS Res Hum Retroviruses; 2019; 35(11-12):1112-1122. PubMed ID: 31578868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
    Cosma A; Nagaraj R; Staib C; Diemer C; Wopfner F; Schätzl H; Busch DH; Sutter G; Goebel FD; Erfle V
    AIDS Res Hum Retroviruses; 2007 Jun; 23(6):782-93. PubMed ID: 17604541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.